BOSTON--(BUSINESS WIRE)--Feb. 26, 2019--
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a
biopharmaceutical company focused on developing and commercializing
medicines seeking to improve the survival and quality of life of cancer
patients, today announced that the Company will host a conference call
and webcast on Tuesday, March 12, 2019 at 4:30 p.m. Eastern Time to
discuss corporate updates and financial results for the fourth quarter
and year ended December 31, 2018.
The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or
(315) 625-3226 (international), five minutes prior to the start of the
call and providing the passcode 2849017. The live, listen-only webcast
of the conference call can be accessed by visiting the investors section
of the Company's website at www.verastem.com.
A replay of the webcast will be archived on the Company's website for 90
days following the call.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005105/en/
Source: Verastem, Inc.
Verastem Oncology:
Erin Cox
Senior Director, Investor
Relations and Corporate Communications
+1 781-469-1553
ecox@verastem.com
Investors:
Joseph Rayne
Argot Partners
+1
617-340-6075
joseph@argotpartners.com